United States Biotechnology & Medical Research

Upstream Bio Inc (UPB)

Track

Track

Upstream Bio Inc. executives recently executed five sell transactions totaling $27,603.72. This activity follows a 46.9% decline in share price over the past quarter. Despite a positive earnings report in August, leadership continues to divest holdings, reflecting a consistent pattern of insider sales observed throughout the current year.
Ticker: UPB Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Upstream Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
Sutherland Everett Rand Chief Executive Officer Executive Director
Transaction date
Sale
Price
424.31
Quantity 15,198 -33.7%
Value US$2,176,482
3.3
Houghton Adam Chief Business Officer Officer
Transaction date
Sale
Price
127.05
Quantity 87,455 +11.2%
Value US$4,385,354
3.1
Deykin Aaron Chief Medical Officer Officer
Transaction date
Sale
Price
75.77
Quantity 14,545 -15.2%
Value US$4,655,810
3.3
Ambrose Allison General Counsel Officer
Transaction date
Sale
Price
5.49
Quantity 485 -3.0%
Value US$2,663
2.1
GRAY MICHAEL CFO and COO Officer
Transaction date
Sale
Price
5.49
Quantity 853 -3.0%
Value US$4,683
3.3
Houghton Adam Chief Business Officer Officer
Transaction date
Sale
Price
6.10
Quantity 700 -2.9%
Value US$4,270
3.1
Deykin Aaron Chief Medical Officer Officer
Transaction date
Planned sale
Price
6.10
Quantity 895 -2.6%
Value US$5,460
3.3
Ambrose Allison General Counsel Officer
Transaction date
Sale
Price
6.10
Quantity 477 -2.9%
Value US$2,910
3.3
Sutherland Everett Rand Chief Executive Officer Executive Director
Transaction date
Sale
Price
6.10
Quantity 2,095 -2.9%
Value US$12,780
2.1
GRAY MICHAEL CFO and COO Officer
Transaction date
Sale
Price
6.10
Quantity 853 -2.9%
Value US$5,203
2.1
GRAY MICHAEL CFO and COO Officer
Transaction date
Sale
Price
9.29
Quantity 852 -2.8%
Value US$7,915
3.1
Deykin Aaron Chief Medical Officer Officer
Transaction date
Sale
Price
9.29
Quantity 894 -2.7%
Value US$8,305
3.3
Sutherland Everett Rand Chief Executive Officer Executive Director
Transaction date
Sale
Price
9.29
Quantity 2,093 -2.8%
Value US$19,444
3.3
Ambrose Allison General Counsel Officer
Transaction date
Sale
Price
9.29
Quantity 475 -2.8%
Value US$4,413
3.3
Houghton Adam Chief Business Officer Officer
Transaction date
Sale
Price
9.29
Quantity 699 -2.8%
Value US$6,494
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 660,000 +16.9%
Value US$11,220,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 165,000 +16.9%
Value US$2,805,000
AI Upstream LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 1,175,000 +inf%
Value US$19,975,000
Chimovits Erez Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 660,000 +16.9%
Value US$11,220,000
Chimovits Erez Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 165,000 +16.9%
Value US$2,805,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-17 2026-09-16 S Sale
3.3
Sutherland Everett Rand

Chief Executive Officer

Executive Director
15,198 -33.7%
424.31
US$2,176,482 		15,198 -33.7% 424.31 US$2,176,482
2026-09-17 2026-09-16 S Sale
3.3
Houghton Adam

Chief Business Officer

Officer
87,455 +11.2%
127.05
US$4,385,354 		87,455 +11.2% 127.05 US$4,385,354
2026-09-17 2026-09-16 S Sale
3.1
Deykin Aaron

Chief Medical Officer

Officer
14,545 -15.2%
75.77
US$4,655,810 		14,545 -15.2% 75.77 US$4,655,810
2026-09-17 2026-09-16 S Sale
3.3
Ambrose Allison

General Counsel

Officer
485 -3.0%
5.49
US$2,663 		485 -3.0% 5.49 US$2,663
2026-09-17 2026-09-16 S Sale
2.1
GRAY MICHAEL

CFO and COO

Officer
853 -3.0%
5.49
US$4,683 		853 -3.0% 5.49 US$4,683
2026-06-17 2026-06-16 S Sale
3.3
Houghton Adam

Chief Business Officer

Officer
700 -2.9%
6.10
US$4,270 		700 -2.9% 6.10 US$4,270
2026-06-17 2026-06-16 PlS Planned sale
3.1
Deykin Aaron

Chief Medical Officer

Officer
895 -2.6%
6.10
US$5,460 		895 -2.6% 6.10 US$5,460
2026-06-17 2026-06-16 S Sale
3.3
Ambrose Allison

General Counsel

Officer
477 -2.9%
6.10
US$2,910 		477 -2.9% 6.10 US$2,910
2026-06-17 2026-06-16 S Sale
3.3
Sutherland Everett Rand

Chief Executive Officer

Executive Director
2,095 -2.9%
6.10
US$12,780 		2,095 -2.9% 6.10 US$12,780
2026-06-17 2026-06-16 S Sale
2.1
GRAY MICHAEL

CFO and COO

Officer
853 -2.9%
6.10
US$5,203 		853 -2.9% 6.10 US$5,203
2026-03-17 2026-03-16 S Sale
2.1
GRAY MICHAEL

CFO and COO

Officer
852 -2.8%
9.29
US$7,915 		852 -2.8% 9.29 US$7,915
2026-03-17 2026-03-16 S Sale
3.1
Deykin Aaron

Chief Medical Officer

Officer
894 -2.7%
9.29
US$8,305 		894 -2.7% 9.29 US$8,305
2026-03-17 2026-03-16 S Sale
3.3
Sutherland Everett Rand

Chief Executive Officer

Executive Director
2,093 -2.8%
9.29
US$19,444 		2,093 -2.8% 9.29 US$19,444
2026-03-17 2026-03-16 S Sale
3.3
Ambrose Allison

General Counsel

Officer
475 -2.8%
9.29
US$4,413 		475 -2.8% 9.29 US$4,413
2026-03-17 2026-03-16 S Sale
3.3
Houghton Adam

Chief Business Officer

Officer
699 -2.8%
9.29
US$6,494 		699 -2.8% 9.29 US$6,494
2024-10-17 2024-10-15 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
660,000 +16.9%
17.00
US$11,220,000 		660,000 +16.9% 17.00 US$11,220,000
2024-10-17 2024-10-15 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
165,000 +16.9%
17.00
US$2,805,000 		165,000 +16.9% 17.00 US$2,805,000
2024-10-17 2024-10-15 B Purchase
AI Upstream LLC
Large shareholder
1,175,000 +inf%
17.00
US$19,975,000 		1,175,000 +inf% 17.00 US$19,975,000
2024-10-17 2024-10-15 B Purchase
Chimovits Erez
Non-Executive Director Large shareholder
660,000 +16.9%
17.00
US$11,220,000 		660,000 +16.9% 17.00 US$11,220,000
2024-10-17 2024-10-15 B Purchase
Chimovits Erez
Non-Executive Director Large shareholder
165,000 +16.9%
17.00
US$2,805,000 		165,000 +16.9% 17.00 US$2,805,000
Explore more

More insider trading research around Upstream Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America